MultiCell Technologies's earnings before interest and taxes (EBIT) for the
three
months ended in Aug. 2015 was $-0.17 Mil.
Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Aug. 2015 was $-0.25 Mil.
EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.
MultiCell Technologies's annualizedROC % for the quarter that ended in Aug. 2015 was -190.07%.
MultiCell Technologies's annualizedROC (Joel Greenblatt) % for the quarter that ended in Aug. 2015 was -68,400.00%.
EBIT is also linked to Joel Greenblatt's definition of earnings yield.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, MultiCell Technologies's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MultiCell Technologies EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, MultiCell Technologies's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where MultiCell Technologies's EV-to-EBIT falls into.
EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.
EBIT for the trailing twelve months (TTM) ended in Aug. 2015 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.25 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MultiCell Technologies (MCET) has a EBIT of $-0.25 Mil as of Aug. 2015. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on MultiCell Technologies.
Is MultiCell Technologies' EBIT too high?
MultiCell Technologies' current EBIT is $-0.25 Mil.
How does MultiCell Technologies' EBIT compare to ERGO and OPLI?
MultiCell Technologies' EBIT of $-0.25 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on MultiCell Technologies. MultiCell Technologies's current EBIT is $-0.25 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MultiCell Technologies stock overvalued right now?
MultiCell Technologies (MCET) has a current EBIT of $-0.25 Mil. The current EBIT is $-0.25 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For MultiCell Technologies (MCET), the current EBIT is $-0.25 Mil as of Aug. 2015. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
MultiCell Technologies Inc is a biopharmaceutical company. It is engaged in developing novel therapeutics and discovery tools for the treatment of neurological disorders, hepatic disease, cancer, and others. Its therapeutic development platform includes several patented techniques used to isolate, characterize, and differentiate stem cells from the human liver or control the immune response at transcriptional and translational levels through dsRNA-sensing molecules, such as Toll-like receptor, RIG-I-like receptor, and MDA-5 signaling. The company's medical device development platform is based on the design of a next-generation bioabsorbable stent, the Ideal BioStent, for interventional cardiology and peripheral vessel applications. All the operations are functioned within United States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MCET has been successfully added to your 